ArticleUnited European gastroenterology journal2018
Association between smoking and risk of primary sclerosing cholangitis: A systematic review and meta-analysis.
Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Environmental shaping of tolerance failure in autoimmune liver diseases: a phenotype-specific framework with primary biliary cholangitis as the strongest model.Journal of translational autoimmunity · 2026Review
- Dietary and Lifestyle Risk Factors in Primary Sclerosing Cholangitis: In Search of Mechanistic Explanations and Health Improvement.The Journal of nutrition · 2025Review
- Systematic replication of smoking disease associations using survey responses and EHR data in the All of Us Research Program.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India.Intestinal research · 2023Article
- Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis.Nature communications · 2023Article
- [Influence of smoking on the gastrointestinal tract : Range of findings].Radiologie (Heidelberg, Germany) · 2022Review
- Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes.Journal of Crohn's & colitis · 2021Article
- Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis.Hepatology international · 2021Article
- Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease.Therapeutic advances in gastroenterology · 2021Article
- Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience.Inflammatory bowel diseases · 2020Observational
- Cigarette smoking and risk of celiac disease: A systematic review and meta-analysis.United European gastroenterology journal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesStudies have suggested that smokers may have a lower risk of primary sclerosing cholangitis (PSC) although the results have been inconsistent. This systematic review and meta-analysis was conducted to summarize all available data to better characterize this association.
methodsA comprehensive literature review was conducted using Medline and Embase databases through January 2018 to identify all studies that compared the risk of PSC among current/former smokers versus nonsmokers. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.
resultsSeven case-control studies with 2,307,393 participants met the eligibility criteria and were included in the meta-analysis. The risk of PSC among current smokers and former smokers was significantly lower than nonsmokers with the pooled odds ratio of 0.31 (95% CI, 0.18-0.53) and 0.52 (95% CI, 0.44-0.61), respectively. The risk remained significantly lower among current smokers and former smokers compared with nonsmokers even when only patients with PSC without inflammatory bowel disease were included.
conclusionsA significantly decreased risk of PSC among current and former smokers was demonstrated in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.